Format

Send to

Choose Destination
Tumour Biol. 2015 Sep;36(10):7473-82. doi: 10.1007/s13277-015-3439-6. Epub 2015 Apr 25.

Japonicone A inhibits the growth of non-small cell lung cancer cells via mitochondria-mediated pathways.

Author information

1
Department of Respiratory Medicine, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China.
2
Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China.
3
Department of Respiratory Medicine, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China. ljqhx@sina.com.
4
Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China. limaolan6@163.com.
5
Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. limaolan6@163.com.
6
Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. limaolan6@163.com.

Abstract

Japonicone A, which is a natural product isolated from the aerial part of Inula japonica Thunb., has a wide range of clinical applications, including anti-inflammation and anti-oxidation. This study investigated the effects of japonicone A on the growth of non-small cell lung cancer (NSCLC) cell lines. The results showed that japonicone A significantly inhibited the growth of NSCLC cell lines in a dose- and time-dependent manner. This product also blocked cell cycle progression at S phase and induced mitochondrial-related apoptosis by upregulating Bax, cleaved caspase-9, cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP) protein levels and by downregulating Bcl-2, cyclin D1, CDC25A, and CDK2 protein levels. In vivo, japonicone A suppressed tumor growth via the same mechanism as that observed in vitro. In conclusion, our study is the first to report that japonicone A has an inhibitory effect on the growth of NSCLC cells, indicating that japonicone A administration is a potential therapeutic approach for future NSCLC treatments.

KEYWORDS:

Apoptosis; Cell cycle arrest; Japonicone A; Mitochondria-mediated pathways; Non-small cell lung cancer

PMID:
25908173
DOI:
10.1007/s13277-015-3439-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center